Saad Mark E 4

What Happened
Mark E. Saad, a director of Axsome Therapeutics (AXSM), received an award of 1,721 restricted stock units (RSUs) on June 5, 2026. The Form 4 reports the acquisition as a derivative award at $0.00 per unit (code A). The RSUs represent contingent rights to receive one share of common stock per RSU and have no immediate cash cost to the insider.

Key Details

• Transaction date: 2026-06-05 (reported on Form 4 filed 2026-06-09).
• Security/details: 1,721 RSUs granted (derivative award) at $0.00 per unit.
• Vesting: RSUs vest in full on the one-year anniversary of the grant (per footnote).
• Shares owned after transaction: Not specified in the provided filing.
• Timeliness: Form 4 was filed on 2026-06-09, within the SEC’s standard two-business-day reporting window for insider transactions (timely).
• Transaction code: A = Award/Grant.

Context
RSUs are a form of equity compensation that convert into shares only when vested; this grant does not represent an immediate open-market purchase or sale. Grants to directors are common as compensation and do not, by themselves, signal a buy or sell decision until vested or sold.